The acute GVHD grading for the Center for International Blood and Marrow Transplant Research (CIBMTR) reporting is based on criteria published by Przepiorka et al (Bone Marrow Transplant,1995;15:825). For your patients with steroid-refractory acute graft-versus-host disease (GVHD)For your patients with steroid-refractory acute graft-versus-host disease (GVHD)STEROID-REFRACTORY PATIENTS CAN BE IDENTIFIED AS EARLY AS 3 DAYS AFTER STARTING TREATMENTApproximately half of patients with aGVHD will not achieve an adequate response to steroids.In each of 2 studies that directly compared outcomes in the steroid-refractory and steroid-dependent populations, both populations had similarly poor outcomes.Patients with steroid-refractory aGVHD can be identified in as early as 3 days after starting treatment with steroids.CIBMTR, Center for International Blood and Marrow Transplant Research; EBMT, European Society for Blood and Marrow Transplantation; NIH, National Institutes of Health. Jakafi Prescribing Information.
Jakafi and the Jakafi logo are registered trademarks of Incyte. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems.
MacMillan ML, Weisdorf DJ, Wagner JE, et al.
You are now leaving the Jakafi.com website.
Faxing Physicians for Follow-up Information through Microsoft Outlook® Using Access®Improving Internal CIBMTR Data Audits: Process Improvement and Time SavingCreative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0)We use cookies to help provide and enhance our service and tailor content and ads. Division of Blood and Marrow Transplantation and Cellular Therapies, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PADivision of Blood and Marrow Transplantation and Cellular Therapies, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PAElectrical Engineering and Computer Sciences, University of California, Berkeley, Berkeley, CA BID, twice daily; CIBMTR, Center for International Blood and Marrow Transplant Research; GI, gastrointestinal; MAGIC, Mount Sinai Acute GVHD International Consortium; MP, methylprednisolone; ORR, overall response rate; REACH, Ruxolitinib in PatiEnts with RefrACtory Graft-Versus-Host Disease After Allogeneic Stem Cell Transplantation.Patients with steroid-refractory aGVHD in REACH1 included those who were steroid-dependent. Jakafi and the Jakafi logo are registered trademarks of Incyte. Wilmington, DE: Incyte Corporation.Jakafi is indicated for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea.Jakafi is indicated for treatment of intermediate or high‐risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF in adults.Jakafi is indicated for treatment of steroid‐refractory acute graft‐versus‐host disease (GVHD) in adult and pediatric patients 12 years and older.
They were defined as patients whoaGVHD, acute graft-versus-host disease; GI, gastrointestinal; PD, progressive disease; REACH, Ruxolitinib in PatiEnts with RefrACtory Graft-Versus-Host Disease After Allogeneic Stem Cell Transplantation.Progression after 3 days of ≥2 mg/kg/day of methylprednisolone or equivalentFailure to improve after 7 days of ≥2 mg/kg/day of methylprednisolone or equivalentTreatment with ≥1 mg/kg/day of methylprednisolone for skin GVHD (or skin plus upper GI GVHD) and development of GVHD disease in an additional organInability to achieve a 50% taper of steroid dose without a return of GVHDJagasia M, Zeiser R, Arbushites M, et al. Jakafi and the Jakafi logo are registered trademarks of Incyte. For US Healthcare Professionals Only